<code id='7F11F7D7E2'></code><style id='7F11F7D7E2'></style>
    • <acronym id='7F11F7D7E2'></acronym>
      <center id='7F11F7D7E2'><center id='7F11F7D7E2'><tfoot id='7F11F7D7E2'></tfoot></center><abbr id='7F11F7D7E2'><dir id='7F11F7D7E2'><tfoot id='7F11F7D7E2'></tfoot><noframes id='7F11F7D7E2'>

    • <optgroup id='7F11F7D7E2'><strike id='7F11F7D7E2'><sup id='7F11F7D7E2'></sup></strike><code id='7F11F7D7E2'></code></optgroup>
        1. <b id='7F11F7D7E2'><label id='7F11F7D7E2'><select id='7F11F7D7E2'><dt id='7F11F7D7E2'><span id='7F11F7D7E2'></span></dt></select></label></b><u id='7F11F7D7E2'></u>
          <i id='7F11F7D7E2'><strike id='7F11F7D7E2'><tt id='7F11F7D7E2'><pre id='7F11F7D7E2'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:42148
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Pfizer highlights cancer drugs it thinks could reignite investor interest
          Pfizer highlights cancer drugs it thinks could reignite investor interest

          AscreenattheNewYorkStockExchangelastNovember.MichaelM.Santiago/GettyImagesPfizerspentmorethanfourhou

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          How to fix the rural physician shortage in the U.S.

          AdobeAsthedeansofthetwopublicmedicalschoolsinNevada,wearewatchingwithprideasourrecentgraduatesprepar